Can a leukemia drug flush out HIV's secret hiding spots?
NCT ID NCT07342491
First seen Jan 18, 2026 · Last updated May 15, 2026 · Updated 12 times
Summary
This early-phase study tests whether dasatinib, a drug used for leukemia, can reduce the hidden HIV reservoir in people already on antiretroviral therapy (ART). Fourteen adults with suppressed HIV will take either dasatinib or a placebo daily for 12 weeks, with close monitoring for safety and changes in immune cells. The goal is to see if the drug can safely lower the amount of virus that stays dormant in the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
1401, University of Washington Positive Research CRS
Seattle, Washington, 98104, United States
-
2501, Case CRS
Cleveland, Ohio, 44106, United States
-
Northwestern University CRS (Site # 2701)
Chicago, Illinois, 60611, United States
Conditions
Explore the condition pages connected to this study.